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Background: Seventeen of 172 included studies in a recent systematic review of blood tests for hepatic fibrosis or
cirrhosis reported diagnostic accuracy results discordant from 2 × 2 tables, and 60 studies reported inadequate data
to construct 2 × 2 tables. This study explores the yield of contacting authors of diagnostic accuracy studies and
impact on the systematic review findings.
Methods: Sixty-six corresponding authors were sent letters requesting additional information or clarification of data
from 77 studies. Data received from the authors were synthesized with data included in the previous review, and
diagnostic accuracy sensitivities, specificities, and positive and likelihood ratios were recalculated.
Results: Of the 66 authors, 68% were successfully contacted and 42% provided additional data for 29 out of 77
studies (38%). All authors who provided data at all did so by the third emailed request (ten authors provided data
after one request). Authors of more recent studies were more likely to be located and provide data compared to
authors of older studies. The effects of requests for additional data on the conclusions regarding the utility of blood
tests to identify patients with clinically significant fibrosis or cirrhosis were generally small for ten out of 12 tests.
Additional data resulted in reclassification (using median likelihood ratio estimates) from less useful to moderately
useful or vice versa for the remaining two blood tests and enabled the calculation of an estimate for a third blood
test for which previously the data had been insufficient to do so. We did not identify a clear pattern for the
directional impact of additional data on estimates of diagnostic accuracy.
Conclusions: We successfully contacted and received results from 42% of authors who provided data for 38% of
included studies. Contacting authors of studies evaluating the diagnostic accuracy of serum biomarkers for hepatic
fibrosis and cirrhosis in hepatitis C patients impacted conclusions regarding diagnostic utility for two blood tests
and enabled the calculation of an estimate for a third blood test. Despite relatively extensive efforts, we were
unable to obtain data to resolve discrepancies or complete 2 × 2 tables for 62% of studies.
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Systematic reviewers often identify studies containing
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such deficiencies can potentially influence the outcome
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unless otherwise stated.inaccurate, or missing data is a major methodological
challenge in conducting systematic reviews.
The problem of missing data in systematic reviews ap-
pears to be common. A 2006 meta-analysis of weight loss
interventions found that 40% of 604 studies had missing
or incomplete data on important variables such as age and
sample size [1]. Similarly, a 2004 review of the effects of
aerobic exercise on lipids and lipoproteins found that 22%
of 174 studies had missing data [2].
One suggested strategy for addressing this issue is for
systematic reviewers to contact study authors to clarifytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Number of authors contacted and provided data
by country





















United Kingdom 5 0
United States 7 4
Total 66 28
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http://www.systematicreviewsjournal.com/content/3/1/107discordant data or to obtain missing data [3,4]. However,
there is little known about the yield of requests for data
or the effects of data obtained through author contact
on the findings of systematic reviews. A 2009 review
found that 50% of 93 systematic reviews in the 25 med-
ical journals with the highest impact factors and 85% of
54 Cochrane systematic reviews published between 2005
and 2006 report contacting authors [5]. Further, 43% of
reviews in the top medical journals and 83% of Cochrane
reviews describe the process of author contact. However,
only 4% of journal reviews and 9% of Cochrane reviews
reported the response rates to author contacts. Evidence
regarding the yield and impact of author requests is
particularly sparse in the area of diagnostic tests.
In 2012, the Pacific Northwest Evidence-based Practice
Center conducted a systematic review to determine the
diagnostic accuracy of various blood tests for hepatic
fibrosis or cirrhosis in patients with chronic hepatitis C
viral infection [6-8]. We found evidence that a number of
blood tests are useful for identifying clinically significant
fibrosis or cirrhosis, based on positive likelihood ratios of
5 to 10, suggesting a potential role as an alternative to
liver biopsy. However, of the 172 included studies, 17
studies reported data that were discordant from 2 × 2
tables (i.e., number of true positives, false positives, true
negatives, and false negatives) calculated from the infor-
mation provided (e.g., prevalence of fibrosis or cirrhosis,
sensitivity, and specificity) in the studies. In addition, 60
studies were missing necessary data for one or more diag-
nostic tests to be included in summary estimates. To the
authors’ knowledge, this is the first study to evaluate the
responsiveness of authors contacted to clarify discordant
data or obtain missing data and the impact of the add-
itional data provided in studies of diagnostic accuracy.
Methods
Included studies
Based on the previous systematic review [6-8], we identi-
fied 17 studies [9-25] that had discrepancies in the data
reported and 60 studies [26-86] that provided insuffi-
cient data to construct 2 × 2 tables at standard cutoffs
for one or more diagnostic tests. We defined studies
with discrepancies as those in which reported measures
of diagnostic accuracy were inconsistent with measures
of diagnostic accuracy calculated from 2 × 2 tables by
values of >0.10 (e.g., reported a positive predictive value
of 0.85 vs. calculated a positive predictive value of 0.70).
For studies in which 2 × 2 table data were not provided,
we calculated values for 2 × 2 tables for commonly re-
ported cutoff values for a positive test, based on the re-
ported sample size, prevalence of the condition of interest
(fibrosis or cirrhosis), sensitivity, and specificity. Studies
for which we could not construct 2 × 2 tables included
those in which some measures of diagnostic accuracy werereported, but other necessary information was missing
(e.g., sample size, prevalence of condition); studies in
which sensitivity and specificity were reported at non-
standard cutoffs; and studies in which an area under the
receiver operating characteristic (AUROC) was reported
without sensitivity or specificity at standard cutoffs.
Contacting authors
We requested data from 66 corresponding authors from
around the world (Table 1) for 77 studies. All publica-
tions were in English and all corresponding authors were
contacted in English. We sent corresponding authors an
initial request for additional data by email. For the con-
venience of authors, we provided labeled 2 × 2 tables
they could fill in and send back to us. If there was no
response to our initial email, after a minimum of three
business days, we sent a second reminder email to the
corresponding author. If there was still no response after
a minimum of eight business days following the initial
email, we sent a second reminder email. After a mini-
mum of ten business days with no response, we then
attempted to contact authors by telephone. If still unable
to reach corresponding authors, we attempted to contact
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http://www.systematicreviewsjournal.com/content/3/1/107the last authors and statisticians, if identifiable. If corre-
sponding authors forwarded our request to other authors,
we sent reminders to these authors. After a minimum of
15 business days from our initial email, we sent a final
email to authors. If we received an automated “out-of-
office” response, we waited until the author had returned
to send further reminders.
Incorporation of data
For studies with discrepancies and cases in which we could
not construct a 2 × 2 table, we requested that authorsAuthors of studies with 
discordant data 
(n = 14 )
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Figure 1 Study authors and results of contact attempts.provide the 2 × 2 data used to generate their estimates of
diagnostic accuracy. For studies that provided only
AUROC or did not report diagnostic accuracy at standard
cutoffs, we asked that authors provide 2 × 2 data for diag-
nostic accuracy at standard cutoffs for the blood test or
tests evaluated.
We recalculated median values and ranges for sensitivity
and specificity at the cutoffs used in the original review
using additional data obtained, and we compared differ-
ences between the updated and original findings. We cate-











































Total authors providing data
(n = 28) 
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http://www.systematicreviewsjournal.com/content/3/1/1075 to 10 or a negative likelihood ratio of 0.1 to 0.2 as mod-
erately useful (no blood test was associated with a positive
likelihood ratio of >10 or negative likelihood ratio <0.1)
[87]. We also reassessed the strength of evidence with the
additional data.
We compared the recalculated sensitivity, specificity,
positive likelihood ratio, and negative likelihood ratio to
the pooled estimates from the initial review. In addition,
we compared the new strength of evidence ratings to
that based on the dataset from the initial review.
Results
Response rate
Of the 66 authors, we were able to contact 45 (68%)
(Figure 1). Of those 45 authors, 28 provided additional
data for 29 studies, including four who provided data-
sets. Among authors whom we were able to contact, rea-
sons for not sending data included the following: no
current access to the data and need for additional time
to find and format the data (e.g., data stored on a floppy
disk).
All authors who provided data did so by the third
request for information (second reminder). We received
information from ten authors after only one request.
Two requests were required for 13 authors, and three
were required for five authors. The average number of
total days between the initial request and the first
reminder was seven, between the first reminder and the
second was 13, and between the second reminder and
the third was 16. The minimum and maximum number
of days between any two contact attempts was three and
34, respectively. Several authors were on holiday or
sabbatical, and we waited until their return to continue
sending reminders which resulted in longer times be-
tween requests. We received no additional information
after three requests and received no additional data in
response to telephone contact.
There was no difference in the likelihood of providing
data between authors of studies with discrepancies com-
pared with authors of studies in which 2 × 2 tables could
not be calculated (54% vs. 40%, p = 0.36). Of the 17 stud-
ies in which there was a discrepancy between reported
results for diagnostic accuracy and constructed 2 × 2
tables, seven of 13 authors provided data on seven
studies [9,12,13,16,18,20,25], including one dataset [18].
We were unable to contact four authors [11,14,19,21],
one author forwarded our request to a colleague who
did not provide the data [22-24], one provided data
for one of two studies [17], and one declined tele-
phone contact [15]. Of the 60 studies missing infor-
mation to generate 2 × 2 tables, 21 of 53 authors
provided additional or confirmatory data on 22 studies
[28,30-35,39,49,51,52,57,62,66,68,69,71,77,78,81,85,86], in-
cluding three datasets [49,77,78]. Reasons for not providingdata were similar to those for authors of studies with
discrepancies. Authors of more recent studies were more
likely to be located and provide data (p = 0.02). The mean
year of publication of studies for which we received
additional data was 2010. The mean year of publication of
studies by contacted authors who did not provide add-
itional data was 2008, while the average publication year for
authors of studies we could not locate was 2007. Country
of publication did not appear to predict the likelihood of
receiving data (Table 1).
Effect on diagnostic accuracy
For diagnosing hepatic fibrosis, additional data were
provided for 12 out of 16 blood tests. The number of
additional studies for specific tests and cutoffs ranged from
zero to nine (zero additional studies occurred when
additional data were obtained, but only for studies with dis-
crepancies, so that one set of data was replaced by another)
(Tables 2 and 3) There was little impact on median
estimates of diagnostic accuracy for the two tests with the
greatest number of additional studies added (five and ten
studies). See the full report for specific tests affected [88].
Additional data for two tests for fibrosis resulted in a
meaningful change in test usefulness from less useful to
moderately useful for one test and from moderately useful
to less useful for one test. Although the additional data re-
sulted in the reclassification of two additional blood tests,
the actual change in median estimates was small to min-
imal. Additional data also enabled us to create estimates
of diagnostic accuracy for fibrosis for one test, for which
data had previously been insufficient to do so.
For diagnosing cirrhosis, additional data were provided
for eight of 16 blood tests. For the test with the greatest
number of additional studies (ten studies), the effect on
median likelihood ratio estimates was minimal [88]. The
number of additional studies ranged from one to five for
other blood tests. Additional data for two tests enabled
reclassification from less useful to moderately useful, but
the impact on the actual estimates was minimal.
We compared the effects of additional data from stud-
ies with discrepancies with the effects of additional data
from studies in which 2 × 2 tables could not be gener-
ated and found no clear pattern suggesting differential
effects on median estimates. We also evaluated effects of
additional data with respect to the original strength of
evidence ratings. The overall strength of evidence rating
did not change for any of the tests for which we ob-
tained additional data. The test for which we received
the most additional data was already rated high strength
of evidence.
Discussion
Our experience demonstrates that obtaining additional
data through author contacts for studies of diagnostic
Table 2 Diagnostic accuracy of tests for fibrosis










Platelets <140 to <163 8 0.56 (0.28–0.89) 0.91 (0.69–1.0) 6.3 (2.3–14) 0.48 (0.16–0.78)
With additional data 10a 0.57 (0.28–0.89) 0.91 (0.58–1.0) 6.3 (1.64–35) 0.48 (0.16–0.78)
API >3.5 or ≥4.0 5 0.70 (0.52–0.82) 0.70 (0.51–0.77) 2.3 (1.7–2.7) 0.43 (0.34–0.67)
With additional data 6a 0.64 (0.52–0.82) 0.69 (0.51–0.77) 2.0 (1.7–2.7) 0.53 (0.34–0.67)
API ≥6.0 5/3b 0.51 (0.19–0.75) 0.90 (0.58–0.96) 5.1 (1.8–7.3) 0.54 (0.43–0.94)
With additional data 6a 0.54 (0.19–0.75) 0.88 (0.58–0.96) 4.5 (1.4–7.3) 0.52 (0.43–0.94)
APRI ≥0.5 to >0.55 28 0.81 (0.29–0.98) 0.55 (0.10–0.94) 1.8 (1.1–4.8) 0.35 (0.08–0.78)
With additional data 40c 0.79 (0.29–0.98) 0.56 (0.10–1.0) 1.8 (1.0–7.5) 0.56 (0.07–0.93)
AST: ALT ratio >1.0 5 0.35 (0.08–0.45) 0.77 (0.62–1.0) 1.5 (1.1–15) 0.84 (0.84–0.98)
With additional data 8a,c 0.36 (0.08–0.59) 0.80 (0.48–1.0) 1.7 (1.1–14) 0.81 (0.65–0.98)
ELF >8.75, >9.0, or >9.78 3 0.85 (0.84–0.86) 0.70 (0.62–0.80) 2.8 (2.3–4.2) 0.21 (0.19–0.23)
With additional data 3a 0.84 (0.62–0.85) 0.80 (0.70–0.86) 4.2 (2.8–4.4) 0.20 (0.19–0.45)
FIB-4 > 1.26 or ≥1.45 6 0.64 (0.62–0.86) 0.68 (0.54–0.75) 2.0 (0.88–2.6) 0.53 (0.21–1.3)
With additional data 9c 0.64 (0.57–0.86) 0.68 (0.28–0.85) 2.0 (0.88–3.7) 0.53 (0.21–1.3)
FIB-4 > 3.25 4 0.50 (0.28–0.86) 0.79 (0.59–0.99) 2.4 (1.3–28) 0.63 (0.21–0.80)
With additional data 7c 0.28 (0.11–0.86) 0.97 (0.59–1.0) 9.3 (1.3–28) 0.74 (0.21–0.89)
FibroIndex >1.25 3 0.94 (0.62–0.97) 0.40 (0.40–0.48) 1.6 (1.2–1.6) 0.15 (0.08–0.79)
With additional data 6c 0.64 (0.54–0.97) 0.57 (0.40–1.0) 1.5 (1.2–2.2) 0.62 (0.08–0.79)
FibroIndex >2.25 or ≥2.25 3 0.30 (0.17–0.36) 0.97 (0.97–1.0) 10,12,∞ 0.72 (0.66–0.83)
With additional data 4c 0.24 (0.14–0.36) 0.99 (0.97–1.0) 10,12,∞ 0.78 (0.66–0.87)
FibroMeter >0.419 to >0.59 3 0.69 (0.64–0.80) 0.81 (0.76–0.81) 3.6 (3.4–3.6) 0.38 (0.26–0.44)
With additional data 5c 0.80 (0.64–0.87) 0.76 (0.64–0.81) 3.3 (2.4–3.6) 0.26 (0.21–0.44)
FibroTest >0.10 to >0.22 6 0.92 (0.88–0.97) 0.38 (0.27–0.56) 1.5 (1.3–1.9) 0.21 (0.11–0.28)
With additional data 9c 0.92 (0.64–0.98) 0.46 (0.21–1.0) 1.7 (1.2–2.2) 0.17 (0.11–0.39)
FibroTest >0.70 or >0.80 5 0.22 (0.20–0.50) 0.96 (0.95–0.98) 5.5 (5.5–13) 0.81 (0.53–0.82)
With additional data 10a,c 0.38 (0.20–0.94) 0.95 (0.36–0.98) 7.6 (1.4–13) 0.65 (0.12–0.82)
Forns Index >4.2 to >4.57 14 0.88 (0.57–0.94) 0.52 (0.20–0.77) 1.8 (1.2–2.2) 0.22 (0.12–0.64)
With additional data 16a,c 0.89 (0.42–0.94) 0.51 (0.20–0.77) 1.8 (0.54–2.2) 0.23 (0.12–2.6)
Forns Index >6.9 10 0.36 (0.18–0.61) 0.94 (0.66–1.0) 6.5 (1.6–18) 0.68 (0.56–0.92)
With additional data 14c 0.40 (0.18–0.81) 0.95 (0.33–1.0) 7.4 (1.2–18) 0.63 (0.22–0.92)
Hepascore >0.46 to ≥0.55 5 0.66 (0.54–0.82) 0.79 (0.65–0.86) 3.1 (2.3–4.5) 0.43 (0.28–0.55)
With additional data 8c 0.65 (0.54–0.82) 0.80 (0.65–0.86) 3.2 (2.3–4.5) 0.44 (0.28–0.55)
Lok Index >0.17 or >0.20 0 NA NA NA NA
With additional data 3c 0.58 (0.48–0.82) 0.80 (0.58–0.81) 2.9 (2.0–3.1) 0.53 (0.31–0.65)
Values in italics indicate a change to above or below a cutoff of 5.0 for positive likelihood ratio or 0.20 for negative likelihood ratio.
ALT serum alanine aminotransferase, API age platelet index, APRI aspartate aminotransferase to platelet ratio index, AST aspartate aminotransferase, ELF enhanced
liver fibrosis, NA not available.
aAdditional data for study(s) with discrepancy in reported data.
bThe first number is the number of samples for sensitivity/the second number is the number of samples for specificity.
cAdditional data for study(s) without 2 × 2 tables.
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to contact the majority of authors (45 out of 66). Most
contacted authors (28 out of 45) provided data, and
several more indicated that they would have had the
data been more readily accessible to them. Although the
effects of the additional data on summary estimates wererelatively small in most cases, the changes had important
implications in assessing the clinical utility of two tests,
in one case moving a blood test into the moderately
useful range and in the other case moving it out of the
moderately useful range. This suggests that while includ-
ing previously unpublished data can result in clinically
Table 3 Diagnostic accuracy of tests for cirrhosis










Platelets <140 to <155 9 0.78 (0.41–0.93) 0.87 (0.84–0.94) 6.0 (2.8–93) 0.25 (0.07–0.63)
With additional data 10a 0.77 (0.41–0.93) 0.86 (0.57–0.99) 5.5 (1.6–93) 0.27 (0.07–0.63)
API ≥6.0 5/3b 0.67 (0.43–0.80) 0.87 (0.81–0.93) 5.2 (2.7–10) 0.38 (0.22–0.68)
With additional data 6a 0.64 (0.12–0.80) 0.88 (0.81–0.99) 5.3 (2.7–17) 0.41 (0.22–0.88)
APRI >1.0 or ≥1.0 19 0.77 (0.33–1.0) 0.75 (0.30–0.87) 3.1 (1.4–4.9) 0.31 (0–0.77)
With additional data 30/29b,c 0.75 (0.13–1.0) 0.77 (0.30–1.0) 3.2 (1.4–10.6) 0.33 (0–0.89)
AST: ALT ratio >1.0 17 0.36 (0.12–0.78) 0.92 (0.59–1.0) 4.5 (1.0–31) 0.70 (0.47–1.0)
With additional data 19a 0.39 (0.10–0.78) 0.93 (0.59–1.0) 5.6 (1.0–31) 0.66 (0.23–1.0)
FIB-4 > 1.45 1 0.90 0.58 2.1 0.17
With additional data 4c 0.89 (0.87–1.0) 0.58 (0.40–0.70) 2.1 (1.7–2.9) 0.19 (0.0–0.23)
FIB-4 > 3.25 1 0.55 0.92 6.9 0.49
With additional data 5c 0.49 (0.40–0.55) 0.93 (0.91–0.95) 6.4 (5.7–8.9) 0.60 (0.49–0.63)
FibroTest >0.56 or >0.66 2 0.85 and 0.82 0.74 and 0.77 3.3 and 36 0.20 and 0.23
With additional data 7c 0.83 (0.27–0.91) 0.74 (0.65–1.0) 3.6 (2.6–3.6) 0.23 (0.11–0.73)
FibroTest >0.73, >0.75, >0.862 7 0.56 (0.30–1.0) 0.81 (0.24–0.96) 2.9 (1.2–10) 0.54 (0.0–0.79)
With additional data 10a,c 0.49 (0.11–0.86) 0.89 (0.55–1.0) 4.3 (1.2–11) 0.57 (0.20–0.89)
Forns Index >4.2 1 0.98 0.27 1.3 0.07
With additional data 6c 0.66 (0.27–1.0) 0.31 (0–1.0) 1.4 (0.27–1.5) 0.07 (0–0.66)
Forns Index >6.9 1 0.67 0.91 7.4 0.36
With additional data 3c 0.66 (0.53–0.67) 0.87 (0.86–0.91) 5.2 (4.2–7.4) 0.39 (0.36–0.53)
Lok Index ≥0.20 or >0.26 6 0.90 (0.67–1.0) 0.50 (0.30–0.82) 1.8 (1.0–4.8) 0.21 (0–0.94)
With additional data 7c 0.90 (0.67–1.0) 0.53 (0.30–0.82) 1.9 (1.0–4.8) 0.19 (0–0.94)
Lok Index ≥0.5 or >0.6 7 0.53 (0.40–0.79) 0.88 (0.60–0.95) 4.4 (1.3–11) 0.53 (0.24–0.80)
With additional data 8c 0.53 (0.23–0.79) 0.91 (0.60–0.97) 5.8 (1.3–11) 0.52 (0.24–0.80)
Values in italics indicate a change to above or below a cutoff of 5.0 for positive likelihood ratio or 0.20 for negative likelihood ratio.
ALT serum alanine aminotransferase, API age platelet index, APRI aspartate aminotransferase to platelet ratio index, AST aspartate aminotransferase.
aAdditional data for study(s) with discrepancy in reported data.
bThe first number is the number of samples for sensitivity/the second number is the number of samples for specificity.
cAdditional data for study(s) without 2 × 2 tables.
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direction of impact may not be readily predictable.
Although we successfully contacted 68% of authors, this
effort was time consuming, not only for us but also for
study authors, who often had to first locate the data before
being able to complete the 2 × 2 tables. In addition, des-
pite our efforts, data to resolve discrepancies or calculate
2 × 2 tables at commonly used cutoffs for sensitivity
and specificity could not be obtained for 48 of 77 (62%)
studies, most frequently because authors could not be
contacted or because they did not have access to the data.
This experience indicates that despite relatively extensive
efforts to obtain additional data, unresolved discrepancies
and missing data remain likely. All data were obtained
with the first three out of five attempted contacts, suggest-
ing that more extensive efforts may be of low yield. In par-
ticular, telephone contact did not produce any additional
information.Limitations
Receiving data was a function of not only whether
authors were accessible and willing to send data but also
whether they were able to communicate in English. As a
result, a slightly higher yield may have been possible if
non-English-speaking authors had been contacted in
their native language.
Conclusions
Contacting authors of studies evaluating the diagnostic
accuracy of serum biomarkers for hepatic fibrosis and
xcirrhosis in hepatitis C patients to obtain additional
data was successful for 29 of 77 studies (38%). This re-
sulted in changes in estimates and reclassification of two
tests for hepatic fibrosis and the inclusion of an add-
itional test for which data had previously been insuffi-
cient to calculate an estimate. Systematic reviewers with
adequate resources should consider contacting authors
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if these studies were published within the past 4
years. However, despite relatively extensive efforts, we
were unable to obtain data to resolve discrepancies or
complete 2 × 2 tables for 48 of 77 studies. Given that
three attempts were needed to obtain even that level
of information, more efficient mechanisms of achiev-
ing better access to information are needed. Requiring
authors of studies on diagnostic accuracy to provide
the 2 × 2 tables at commonly used cutoffs in the ori-
ginal study publication (or in the results of publicly
available trial registries such as ClinicalTrials.gov) or
requiring authors to make their datasets publicly available
would save time, enable systematic reviewers to synthesize
data more readily and completely, and enable more
transparent verification of authors’ estimates of diag-
nostic accuracy.
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